SEC on trail of Onyx 'insider' trading scam
This article was originally published in Scrip
Executive Summary
Someone forgot to tell the accused yet-to-be identified insider traders of Onyx Pharmaceuticals shares the US Securities and Exchange Commission (SEC) has been paying particularly close attention to stock activity involving biopharmaceutical companies.